Page 88 - InvestinAlberta-EDA-2024-2

MAKING IT EASIER TO SCAN
A made-in-Alberta solution will help elevate men’s health
BY LAURENCE HEINEN
An exciting innovation to support men’s health on a global scale was unveiled as part of Alberta’s inaugural Life Sciences Week in Edmonton, capital city of Alberta, in late September 2023.
Nanostics Inc. an Edmonton-based medical device and biotechnology company, announced the availability
of its ClarityDX Prostate test at the company’s newly accredited clinical lab.
“There was great excitement in
the air for Nanostics and for Alberta’s life sciences sector,” said Tim Murphy, vice president of health for Alberta Innovates, Alberta’s innovation engine, which provides funding and assistance to researchers, entrepreneurs and industry to grow the local economy. “It’s been a long-term investment as we move from lab to market. It takes a long time and we’ve been with this since 2013, investing in their program and the development of the ClarityDX product. It’s not an overnight success story.”
In Alberta, men are screened for prostate cancer using a simple prostate- specific antigen (PSA) test. Elevated levels of PSA in the blood could be an indication of prostate cancer, but there are also several non-cancer-related reasons PSA levels may be elevated.
CLARITYDX PROSTATE IS AN EASY-TO-DO BLOOD TEST THAT IS THREE TIMES MORE ACCURATE AT DETECTING PROSTATE CANCER
88 INVEST IN ALBERTA 2 0 2 4
EDAAlberta.ca
FOR CANCER